T-cell product improves outcomes of haplo-HSCT



HSCT preparation
Photo by Chad McNeeley
Preliminary results of a phase 1/2 study suggest the T-cell product BPX-501 lowers the risks associated with haploidentical hematopoietic stem cell transplant (haplo-HSCT). In this ongoing study, researchers are testing BPX-501 in pediatric patients undergoing haplo-HSCT to treat a range of hematologic disorders. Patients treated thus far... [Read Article]

Combo with daratumumab could be alternative to ASCT in MM



Attendees at ASCO 2017 Annual Meeting
Photo © ASCO/Scott Morgan 2017
Results of an open-label phase 1b study of daratumumab combined with carfilzomib, lenalidomide, and dexamethasone (KRd) in newly diagnosed multiple myeloma (MM) patients have shown the combination to be highly effective, with an overall response rate of 100%. Ninety-one percent of patients achieved a... [Read Article]

Differences emerge in new guidelines for managing FN in kids



Doctor evaluating patient
Photo courtesy of the CDC
A multidisciplinary, international panel of experts has updated earlier clinical practice guidelines on managing fever and neutropenia (FN) in children with cancer and in those undergoing hematopoietic stem cell transplantation (HSCT). And while most of the recommendations remained unchanged from the 2012 guidelines, a few key... [Read Article]

Group creates ‘authentic’ HSCs from endothelial cells



Hematopoietic stem cells
in the bone marrow
Researchers say they have found a way to convert adult mouse endothelial cells into “authentic” hematopoietic stem cells (HSCs). The team says these HSCs have a transcriptome and long-term self-renewal capacity that are similar to those of adult HSCs that are produced naturally. In addition, the lab-generated... [Read Article]

Intensive chemo upfront means DHL patients can skip HSCT



Cancer patient receiving chemotherapy
Photo by Rhoda Baer
A new study suggests that patients with double-hit lymphoma (DHL) in first remission only benefit from an autologous hematopoietic stem cell transplant (auto-HSCT) if they received standard frontline chemotherapy. Researchers looked at long-term outcomes for DHL patients who achieved remission and, overall, found that auto-HSCT... [Read Article]

CMV matching improves survival in HSCT recipients



Micrograph showing
CMV infection
Matching the cytomegalovirus (CMV) status of the donor and recipient of a hematopoietic stem cell transplant (HSCT) can significantly improve the recipient’s survival, according to a study published in Bone Marrow Transplantation. In fact, researchers said they found evidence to suggest that CMV matching may abrogate the effect of... [Read Article]

Study shows similar outcomes with RIC and MAC in MDS



HSCT preparation
Photo by Chad McNeeley
Results of a phase 3 trial revealed similar outcomes in patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat myelodysplastic syndromes (MDS), regardless of the conditioning regimen they received. Rates of engraftment, graft-vs-host disease (GVHD), relapse, and survival were similar between patients who received reduced-intensity... [Read Article]

Method could prevent GVHD while preserving GVL effect



Micrograph showing GVHD
Image from PLOS ONE
Researchers believe they have found a way to prevent graft-versus-host disease (GVHD) after hematopoietic stem cell transplant (HSCT) while preserving a strong graft-versus-leukemia (GVL) effect. In experiments with mice, the team found that temporary in vivo depletion of CD4+ T cells soon after HSCT prevented GVHD... [Read Article]